Disparities in cardio-oncology: Implication of angiogenesis, inflammation, and chemotherapy

Area of Science:

• Cardio-oncology
• Cardiovascular disease
• Cancer therapy

Background:

• Cancer and cardiovascular diseases are leading causes of death in the US.
• Cancer treatments, while improving survival, increase cardiac failure risk.
• Mechanisms linking cancer treatments to cardiotoxicity are poorly understood.

Purpose of the Study:

• To discuss how current biomarkers of inflammation and angiogenesis relate to cardiovascular health disparities.
• To highlight the need for better understanding of cardiotoxicity in diverse populations.
• To address the impact of gender and racial disparities in cardio-oncology.

Main Methods:

• Review of current literature on cardiotoxicity biomarkers.
• Analysis of the role of inflammation and angiogenesis in cancer treatment-related cardiac dysfunction.
• Examination of existing data on gender and racial disparities in cardiotoxicity.

Main Results:

• Biomarkers of inflammation and angiogenesis are used to detect cardiotoxicity early.
• Cancer therapies can induce systemic effects on the heart and vasculature.
• There is a significant gap in data regarding cardiotoxicity variations across diverse populations.

Conclusions:

• Early detection of cardiotoxicity through biomarkers like inflammation and angiogenesis is crucial.
• Addressing gender and racial disparities in cardiotoxicity is an emerging focus in cardio-oncology.
• Further research is needed to understand and mitigate cardiotoxicity in diverse patient groups.